Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons

• Published in: Clinical infectious diseases Vol. 61; no. suppl_5; pp. S501 - S506
• Main Authors: Enwere, Godwin C., Paranjape, Gandhali, Kulkarni, Prasad S., Ginde, Manisha, Hartmann, Katharina, Viviani, Simonetta, Chaumont, Julie, Martellet, Lionel, Makadi, Marie-Francoise, Ivinson, Karen, Marchetti, Elisa, Herve, Jacques, Kertson, Kim, LaForce, F. Marc, Preziosi, Marie-Pierre
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 15-11-2015
• Subjects: Clinical trials; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - pathology; Humans; Immunization; Meningococcal Vaccines - administration & dosage; Neisseria meningitidis; Rotavirus; Safety; SEROLOGIC AND SAFETY STUDIES OF A GROUP A MENINGOCOCCAL CONJUGATE VACCINE; Side effects; The Meningitis Vaccine Project: The Development, Licensure, , and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa; Vaccines; uniform methods; MenAfriVac; effective communication; safety monitoring and reporting
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/cid/civ509

Background. The determination of the safety profile of any vaccine is critical to its widespread use in any population. In addition, the application of international guidelines to fit local context could be a challenging but important step toward obtaining quality safety data. Methods. In clinical studies of PsA-TT (MenAfriVac), safety was monitored immediately after vaccination, at 4–7 days for postimmunization local and systemic reactions, within 28 days for adverse events, and throughout the duration of study for serious adverse events. Initial and ongoing training of sites' staff were undertaken during the studies, and a data and safety monitoring board reviewed all the data during and after the studies. Results. The safety of PsA-TT was evaluated according to international standards despite obvious challenges in remote areas where these studies were conducted. These challenges included the need for uniformity of methods, timely reporting in the context of frequent communication problems, occurrence of seasonal diseases such as malaria and rotavirus diarrhea, and healthcare systems that required improvement. Conclusions. The trials of PsA-TT highlighted the value of a robust vaccine development plan and design so that lessons learned in initial studies were incorporated into the subsequent ones, initial training and periodic retraining, strict monitoring of all procedures, and continuous channel of communication with all stakeholders that enabled the application of international requirements to local settings, with high quality of data.